Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.62
+0.56 (2.23%)
Sep 20, 2024, 4:00 PM EDT - Market closed
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 26.92, with a low estimate of 10 and a high estimate of 36. The average target predicts an increase of 5.07% from the current stock price of 25.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRIX stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 5 | 6 | 7 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 10 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $27 → $30 | Buy | Maintains | $27 → $30 | +17.10% | Sep 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $27 | Buy | Maintains | $25 → $27 | +5.39% | Aug 14, 2024 |
| Truist Securities | Truist Securities | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +40.52% | Jul 31, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $34 | Buy | Maintains | $31 → $34 | +32.71% | Jul 15, 2024 |
| Barclays | Barclays | Buy Maintains $20 → $31 | Buy | Maintains | $20 → $31 | +21.00% | Jul 15, 2024 |
Financial Forecast
Revenue This Year
59.43M
from 76.99M
Decreased by -22.80%
Revenue Next Year
65.33M
from 59.43M
Increased by 9.92%
EPS This Year
-2.88
from -2.65
EPS Next Year
-2.82
from -2.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 84.0M | 94.5M | 221.0M | ||
| Avg | 59.4M | 65.3M | 79.0M | ||
| Low | 28.4M | 32.7M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.1% | 59.0% | 238.2% | ||
| Avg | -22.8% | 9.9% | 20.9% | ||
| Low | -63.1% | -45.0% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.56 | -2.02 | -1.28 | ||
| Avg | -2.88 | -2.82 | -3.01 | ||
| Low | -3.22 | -3.47 | -4.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.